$INSM News

$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

Wolfe Research Downgrades Insmed to Peer Perform

HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target

Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?

$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

Insmed stock falls as CFO Sara Bonstein to step down

Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed

Insmed Announces CFO Transition

Insmed Q2 2026 Earnings Call Transcript

Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE

Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case